Pipeline Alert: Stoke Therapeutics CEO Sales Trigger

🚀 Battle Card: Stoke Therapeutics, Inc.

• Ian F. Smith, Chief Executive Officer · 🔗 [LinkedIn](https://www.linkedin.com/company/stoke-therapeutics-inc-/)

• This CEO change is a prime Stoke Therapeutics, Inc. sales trigger: new leadership to accelerate global Phase 3 execution and commercial readiness. → Source

• Accelerating late-stage clinical operations

• Scaling commercial launch capabilities for rare disease therapies

• Primary: Clinical trial management platform → Streamlined global Phase 3 execution (ride the Stoke Therapeutics, Inc. sales trigger momentum)

• Expansion: Commercial launch support services → Rapid market entry for zorevunersen

• HQ: Bedford, MA

• Employees: ≈ 200

• Rev: ≈ $5 M

• Website: [stoketherapeutics.com](https://www.stoketherapeutics.com/)

🤼 Competitive Intel

• Ionis Pharmaceuticals — Antisense platform
• Unique edge: Pioneer in ASO development
• Evaluated by VP R&D for platform maturity

• Sarepta Therapeutics — Gene/RNA therapy
• Unique edge: Established rare disease commercial footprint
• Evaluated by Chief Commercial Officer for launch expertise

• Biogen — Neurology/pharma partner
• Unique edge: Deep collaboration on zorevunersen commercialization
• Evaluated by CFO for partnership leverage

• Alnylam Pharmaceuticals — RNAi therapies
• Unique edge: FDA-approved RNA therapeutics track record
• Evaluated by VP Clinical Ops for regulatory know-how

• Wave Life Sciences — Stereopure oligonucleotides
• Unique edge: High-fidelity oligo tech
• Evaluated by Head of Translational Medicine for trial design

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑a clinical trial management platform❑
PROOF_METRIC  = ❑30% faster trial enrollment❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Ian F.
COMPANY     = Stoke Therapeutics, Inc.
DEPT        = Executive
SIZE        = ≈ 5
BOTTLENECK  = scaling late-stage clinical operations
EVENT       = CEO appointment
DETAIL      = your appointment as CEO
PAIN        = accelerating Phase 3 execution
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251006657082&div=41152219
SIM_CO      = Ionis Pharmaceuticals
WIN_METRIC  = 30% faster trial enrollment
NEXT_SIZE   = ≈ 10
EMP_EST     = ≈ 200
REV_EST     = ≈ $5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈ 5-person Executive

Ian F.—noticed your Executive team is ≈ 5.

That’s when scaling late-stage clinical operations slows growth.

We helped Ionis Pharmaceuticals fix this with a clinical trial management platform.

Result: 30% faster trial enrollment.  
Quick call?

PS—next bottleneck hits ≈ 10.

DM ≤45 words, TONE:
Saw your post about your appointment as CEO — accelerating Phase 3 execution.  
a clinical trial management platform. 30% faster trial enrollment.  
Quick chat?